Energenesis Biomedical CO.,LTD. (TPE:6657)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
56.50
+0.10 (0.18%)
Aug 1, 2025, 1:30 PM CST
0.18%
Market Cap5.01B
Revenue (ttm)7.55M
Net Income (ttm)-285.26M
Shares Out88.66M
EPS (ttm)-3.60
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume262,743
Average Volume379,250
Open56.50
Previous Close56.40
Day's Range55.00 - 57.20
52-Week Range45.90 - 85.60
Beta0.30
RSI34.27
Earnings DateAug 8, 2025

About SolarWinds

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERG... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 35
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6657
Full Company Profile

Financial Performance

In 2024, TPE:6657's revenue was 7.75 million, an increase of 8.26% compared to the previous year's 7.16 million. Losses were -231.08 million, -11.25% less than in 2023.

Financial Statements

News

There is no news available yet.